Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC. We performed...
Saved in:
Published in | Frontiers in immunology Vol. 14; p. 1119168 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
17.04.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC.
We performed a meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines. We searched the literature from PubMed, Embase, Web of Science, and the Cochrane Library up to December 5, 2022. Hazard ratios (HR) and their 95% confidence intervals (95% CI) were calculated to analyze the overall survival (OS), recurrence-free survival (RFS), and time to relapse. The quality of the studies was assessed using the Newcastle-Ottawa scale. Publication bias was assessed using a funnel plot and Egger's test.
Ten trials with 1944 cases were included in this meta-analysis. The results showed that the low-PD-L1 group had a statistically significant advantage in OS (HR, 1.57; 95% CI, 1.38-1.79, P <0.00001), RFS (HR, 1.62; 95% CI, 1.34-1.97, P <0.00001), and time to relapse (HR, 1.60; 95% CI, 1.25-2.05, P = 0.0002) compared with the high-PD-L1 group. High programmed cell death (PD1)levels, on the other hand, were correlated with poorer OS (HR, 1.96; 95% CI, 1.43-2.70; P <0.0001) and RFS (HR, 1.87; 95% CI, 1.21-2.91; P = 0.005). Multivariate analysis showed that PD-L1 could act as an independent predictor for OS (HR, 1.48; 95% CI, 1.14-1.91; P = 0.003) and RFS (HR, 1.74; 95% CI, 1.22-2.47; P = 0.002), and PD1 acted as an independent predictor for OS (HR, 1.66; 95% CI, 1.15-2.38; P = 0.006).
This meta-analysis demonstrated that high PD-L1/PD1 expression is associated with poor survival in ICC. PD-L1/PD1 may be a valuable prognostic and predictive biomarker and potential therapeutic target in ICC.
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022380093. |
---|---|
AbstractList | BackgroundProgrammed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC. MethodsWe performed a meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines. We searched the literature from PubMed, Embase, Web of Science, and the Cochrane Library up to December 5, 2022. Hazard ratios (HR) and their 95% confidence intervals (95% CI) were calculated to analyze the overall survival (OS), recurrence-free survival (RFS), and time to relapse. The quality of the studies was assessed using the Newcastle-Ottawa scale. Publication bias was assessed using a funnel plot and Egger's test. ResultsTen trials with 1944 cases were included in this meta-analysis. The results showed that the low-PD-L1 group had a statistically significant advantage in OS (HR, 1.57; 95% CI, 1.38-1.79, P <0.00001), RFS (HR, 1.62; 95% CI, 1.34-1.97, P <0.00001), and time to relapse (HR, 1.60; 95% CI, 1.25-2.05, P = 0.0002) compared with the high-PD-L1 group. High programmed cell death (PD1)levels, on the other hand, were correlated with poorer OS (HR, 1.96; 95% CI, 1.43-2.70; P <0.0001) and RFS (HR, 1.87; 95% CI, 1.21-2.91; P = 0.005). Multivariate analysis showed that PD-L1 could act as an independent predictor for OS (HR, 1.48; 95% CI, 1.14-1.91; P = 0.003) and RFS (HR, 1.74; 95% CI, 1.22-2.47; P = 0.002), and PD1 acted as an independent predictor for OS (HR, 1.66; 95% CI, 1.15-2.38; P = 0.006). ConclusionThis meta-analysis demonstrated that high PD-L1/PD1 expression is associated with poor survival in ICC. PD-L1/PD1 may be a valuable prognostic and predictive biomarker and potential therapeutic target in ICC. Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022380093. Background Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC. Methods We performed a meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines. We searched the literature from PubMed, Embase, Web of Science, and the Cochrane Library up to December 5, 2022. Hazard ratios (HR) and their 95% confidence intervals (95% CI) were calculated to analyze the overall survival (OS), recurrence-free survival (RFS), and time to relapse. The quality of the studies was assessed using the Newcastle-Ottawa scale. Publication bias was assessed using a funnel plot and Egger’s test. Results Ten trials with 1944 cases were included in this meta-analysis. The results showed that the low-PD-L1 group had a statistically significant advantage in OS (HR, 1.57; 95% CI, 1.38–1.79, P <0.00001), RFS (HR, 1.62; 95% CI, 1.34–1.97, P <0.00001), and time to relapse (HR, 1.60; 95% CI, 1.25–2.05, P = 0.0002) compared with the high-PD-L1 group. High programmed cell death (PD1)levels, on the other hand, were correlated with poorer OS (HR, 1.96; 95% CI, 1.43–2.70; P <0.0001) and RFS (HR, 1.87; 95% CI, 1.21–2.91; P = 0.005). Multivariate analysis showed that PD-L1 could act as an independent predictor for OS (HR, 1.48; 95% CI, 1.14–1.91; P = 0.003) and RFS (HR, 1.74; 95% CI, 1.22–2.47; P = 0.002), and PD1 acted as an independent predictor for OS (HR, 1.66; 95% CI, 1.15–2.38; P = 0.006). Conclusion This meta-analysis demonstrated that high PD-L1/PD1 expression is associated with poor survival in ICC. PD-L1/PD1 may be a valuable prognostic and predictive biomarker and potential therapeutic target in ICC. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42022380093. Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC. We performed a meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines. We searched the literature from PubMed, Embase, Web of Science, and the Cochrane Library up to December 5, 2022. Hazard ratios (HR) and their 95% confidence intervals (95% CI) were calculated to analyze the overall survival (OS), recurrence-free survival (RFS), and time to relapse. The quality of the studies was assessed using the Newcastle-Ottawa scale. Publication bias was assessed using a funnel plot and Egger's test. Ten trials with 1944 cases were included in this meta-analysis. The results showed that the low-PD-L1 group had a statistically significant advantage in OS (HR, 1.57; 95% CI, 1.38-1.79, P <0.00001), RFS (HR, 1.62; 95% CI, 1.34-1.97, P <0.00001), and time to relapse (HR, 1.60; 95% CI, 1.25-2.05, P = 0.0002) compared with the high-PD-L1 group. High programmed cell death (PD1)levels, on the other hand, were correlated with poorer OS (HR, 1.96; 95% CI, 1.43-2.70; P <0.0001) and RFS (HR, 1.87; 95% CI, 1.21-2.91; P = 0.005). Multivariate analysis showed that PD-L1 could act as an independent predictor for OS (HR, 1.48; 95% CI, 1.14-1.91; P = 0.003) and RFS (HR, 1.74; 95% CI, 1.22-2.47; P = 0.002), and PD1 acted as an independent predictor for OS (HR, 1.66; 95% CI, 1.15-2.38; P = 0.006). This meta-analysis demonstrated that high PD-L1/PD1 expression is associated with poor survival in ICC. PD-L1/PD1 may be a valuable prognostic and predictive biomarker and potential therapeutic target in ICC. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022380093. |
Author | Bie, Jun Xu, Guohui Xian, Feng Ren, Dacheng |
AuthorAffiliation | 3 Department of Interventional Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China , Chengdu , China 1 School of Medicine, University of Electronic Science and Technology of China , Chengdu , China 2 Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College , Nanchong , China |
AuthorAffiliation_xml | – name: 1 School of Medicine, University of Electronic Science and Technology of China , Chengdu , China – name: 2 Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College , Nanchong , China – name: 3 Department of Interventional Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China , Chengdu , China |
Author_xml | – sequence: 1 givenname: Feng surname: Xian fullname: Xian, Feng organization: Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College, Nanchong, China – sequence: 2 givenname: Dacheng surname: Ren fullname: Ren, Dacheng organization: Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College, Nanchong, China – sequence: 3 givenname: Jun surname: Bie fullname: Bie, Jun organization: Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College, Nanchong, China – sequence: 4 givenname: Guohui surname: Xu fullname: Xu, Guohui organization: Department of Interventional Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37138876$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkk1v3CAQhq0qVZOm-QM9VBx78RYYbKCXqor6ESlSe2jPaBaDl8gGF7xpc-pfr53dRgkX0MvMM8PwvqxOYoquql4zugFQ-p0P47jfcMphwxjTrFXPqjPWtqIGzsXJo_NpdVHKDV2W0ADQvKhOQTJQSrZn1d_vOfUxlTlYcovD3pHkybRoGcfRdcS6YSCdw3lHhtBj7Agj7s-UXSkhRRIimXAOLs6F_A5LUIhzxp1bRUvsLg0Y-5AsZhtiGvE9QTK6GWuMONyVUF5Vzz0OxV0c9_Pq5-dPPy6_1tffvlxdfryurWj1XHvNOislY9KDln4rkVulWqUadKIB4Ei3SjoQHrnvGim1UB6aDlpOGbUNnFdXB26X8MZMOYyY70zCYO6FlHuDeel5cEY63yKTLXDQgiFTEjVDBYpvvaNdt7A-HFjTfrvMyLr1zcMT6NObGHamT7eGUSa0ou1CeHsk5PRr78psxlDWUWN0aV8MV1Q3ApSEJZQfQm1OpWTnH-owalYnmHsnmNUJ5uiEJenN4w4fUv7_O_wDdvi0Qg |
CitedBy_id | crossref_primary_10_3389_fimmu_2024_1378760 crossref_primary_10_1111_liv_15984 crossref_primary_10_1016_j_biopha_2024_116659 crossref_primary_10_3892_ijo_2023_5585 |
Cites_doi | 10.3389/fphar.2022.894407 10.1016/j.suc.2020.02.013 10.1007/s10654-010-9491-z 10.18632/oncotarget.12810 10.7150/thno.28742 10.3390/cancers14092190 10.1136/bmj.n160 10.1016/j.molmed.2014.10.009 10.7150/thno.36276 10.1136/jitc-2020-001638 10.4143/crt.2016.066 10.1002/cncr.34552 10.1093/annonc/mdv615 10.3389/fimmu.2022.954910 10.1016/j.jhep.2019.10.009 10.1186/s12885-019-6276-y 10.2217/fon-2020-0683 10.1080/2162402X.2021.1933332 10.1016/j.canlet.2019.02.022 10.1186/s12967-022-03342-6 10.1159/000514404 10.1007/s11934-019-0866-8 10.1593/tlo.13256 10.3389/fmed.2020.00368 10.3389/fimmu.2021.799822 10.1007/s12022-020-09630-5 10.1038/s41379-020-00702-9 10.1136/bmj.n71 10.3390/jpm12071073 10.1111/cpr.12571 10.1002/path.5280 10.1016/j.tcb.2018.08.005 10.1371/journal.pone.0182692 10.1038/bjc.2015.101 10.1016/j.jtho.2016.04.014 10.1136/bmj.327.7414.557 10.12998/wjcc.v10.i27.9743 10.2147/OTT.S250454 10.1186/1745-6215-8-16 10.1097/CJI.0000000000000187 10.1007/s00251-017-1015-5 10.21037/tcr.2020.04.11 10.18632/oncotarget.15532 10.1186/s12957-020-02082-5 10.2147/OTT.S288982 10.1038/s41416-021-01569-6 10.7150/jca.46158 10.1016/j.immuni.2018.03.014 10.3389/fonc.2018.00386 |
ContentType | Journal Article |
Copyright | Copyright © 2023 Xian, Ren, Bie and Xu. Copyright © 2023 Xian, Ren, Bie and Xu 2023 Xian, Ren, Bie and Xu |
Copyright_xml | – notice: Copyright © 2023 Xian, Ren, Bie and Xu. – notice: Copyright © 2023 Xian, Ren, Bie and Xu 2023 Xian, Ren, Bie and Xu |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fimmu.2023.1119168 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
EndPage | 1119168 |
ExternalDocumentID | oai_doaj_org_article_7ef6a176323941a187a91a8382bfe0dd 10_3389_fimmu_2023_1119168 37138876 |
Genre | Research Support, Non-U.S. Gov't Meta-Analysis Systematic Review |
GrantInformation_xml | – fundername: ; |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CGR CUY CVF DIK EBS ECM EIF EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW IPNFZ KQ8 M48 M~E NPM OK1 PGMZT RIG RNS RPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c469t-f91dc77117f397fb7a2c886885ae45332a0b87e34fa2fd577948f35d362010c53 |
IEDL.DBID | RPM |
ISSN | 1664-3224 |
IngestDate | Tue Oct 22 15:14:08 EDT 2024 Tue Sep 17 21:31:04 EDT 2024 Fri Oct 25 03:26:29 EDT 2024 Thu Sep 26 18:58:15 EDT 2024 Sat Sep 28 08:14:34 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | meta-analysis intrahepatic carcinoma prognostic value programmed cell death ligand 1 (PDL1) programmed cell death 1 (PD-1) |
Language | English |
License | Copyright © 2023 Xian, Ren, Bie and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c469t-f91dc77117f397fb7a2c886885ae45332a0b87e34fa2fd577948f35d362010c53 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Reviewed by: Albino Eccher, Integrated University Hospital Verona, Italy; Bing Feng, Pennington Biomedical Research Center, United States; Jian Zhou, Chinese Academy of Sciences (CAS), China Edited by: Hongda Liu, Nanjing Medical University, China This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149806/ |
PMID | 37138876 |
PQID | 2809543873 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_7ef6a176323941a187a91a8382bfe0dd pubmedcentral_primary_oai_pubmedcentral_nih_gov_10149806 proquest_miscellaneous_2809543873 crossref_primary_10_3389_fimmu_2023_1119168 pubmed_primary_37138876 |
PublicationCentury | 2000 |
PublicationDate | 2023-04-17 |
PublicationDateYYYYMMDD | 2023-04-17 |
PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-17 day: 17 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2023 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Xiong (B25) 2020; 13 Chen (B6) 2016; 27 Stutvoet (B9) 2019; 249 Kim (B39) 2021; 99 Xie (B45) 2022; 13 Nunes-Xavier (B41) 2019; 20 Kelley (B2) 2020; 72 Gu (B18) 2017; 12 Yugawa (B37) 2021; 34 Liu (B46) 2020; 7 Mejia (B1) 2020; 100 Yu (B12) 2016; 11 Ha (B31) 2016; 7 Tao (B34) 2020; 9 Ohaegbulam (B4) 2015; 21 Wu (B23) 2021; 14 Page (B26) 2021; 372 Yin (B20) 2021; 10 Abiko (B40) 2015; 112 Zhu (B44) 2022; 10 Page (B27) 2021; 372 Huang (B14) 2017; 40 Ma (B16) 2018; 8 Zheng (B38) 2022; 129 Munari (B48) 2022; 13 Lu (B22) 2019; 9 Wang (B24) 2021; 12 Wang (B13) 2021; 17 Higgins (B30) 2003; 327 Stang (B29) 2010; 25 Lan (B32) 2022; 126 Zhao (B8) 2019; 52 Zhang (B21) 2017; 8 Tierney (B28) 2007; 8 Salmaninejad (B42) 2018; 70 Yang (B36) 2022; 20 Wei (B7) 2019; 450 Marletta (B47) 2022; 12 Tan (B33) 2022; 14 Galluzzi (B10) 2019; 29 Peng (B19) 2021; 9 Dong (B5) 2018; 8 Sun (B3) 2018; 48 Cao (B11) 2019; 19 Tian (B35) 2020; 18 Jung (B15) 2017; 49 Kang (B43) 2013; 6 Chen (B17) 2020; 11 Girolami (B49) 2020; 31 |
References_xml | – volume: 13 year: 2022 ident: B45 article-title: Lenvatinib combined with a PD-1 inhibitor as effective therapy for advanced intrahepatic cholangiocarcinoma publication-title: Front Pharmacol doi: 10.3389/fphar.2022.894407 contributor: fullname: Xie – volume: 100 year: 2020 ident: B1 article-title: Primary liver cancers: intrahepatic cholangiocarcinoma and hepatocellular carcinoma publication-title: Surg Clin North Am doi: 10.1016/j.suc.2020.02.013 contributor: fullname: Mejia – volume: 25 year: 2010 ident: B29 article-title: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses publication-title: Eur J Epidemiol doi: 10.1007/s10654-010-9491-z contributor: fullname: Stang – volume: 7 year: 2016 ident: B31 article-title: Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy publication-title: Oncotarget doi: 10.18632/oncotarget.12810 contributor: fullname: Ha – volume: 8 year: 2018 ident: B16 article-title: Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma publication-title: Theranostics doi: 10.7150/thno.28742 contributor: fullname: Ma – volume: 14 year: 2022 ident: B33 article-title: PD-1+T-Cells correlate with nerve fiber density as a prognostic biomarker in patients with resected perihilar cholangiocarcinoma publication-title: Cancers doi: 10.3390/cancers14092190 contributor: fullname: Tan – volume: 372 year: 2021 ident: B26 article-title: PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews publication-title: BMJ doi: 10.1136/bmj.n160 contributor: fullname: Page – volume: 21 start-page: 24 year: 2015 ident: B4 article-title: Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway publication-title: Trends Mol Med doi: 10.1016/j.molmed.2014.10.009 contributor: fullname: Ohaegbulam – volume: 9 year: 2019 ident: B22 article-title: Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors publication-title: Theranostics doi: 10.7150/thno.36276 contributor: fullname: Lu – volume: 9 start-page: e001638 year: 2021 ident: B19 article-title: CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer publication-title: J For Immunotherapy Cancer doi: 10.1136/jitc-2020-001638 contributor: fullname: Peng – volume: 49 year: 2017 ident: B15 article-title: Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma publication-title: Cancer Res Treat doi: 10.4143/crt.2016.066 contributor: fullname: Jung – volume: 129 year: 2022 ident: B38 article-title: The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery publication-title: Cancer doi: 10.1002/cncr.34552 contributor: fullname: Zheng – volume: 27 year: 2016 ident: B6 article-title: Regulation of PD-L1: a novel role of pro-survival signalling in cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdv615 contributor: fullname: Chen – volume: 13 year: 2022 ident: B48 article-title: Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection publication-title: Front In Immunol doi: 10.3389/fimmu.2022.954910 contributor: fullname: Munari – volume: 72 year: 2020 ident: B2 article-title: Systemic therapies for intrahepatic cholangiocarcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2019.10.009 contributor: fullname: Kelley – volume: 19 start-page: 1022 year: 2019 ident: B11 article-title: Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma publication-title: BMC Cancer doi: 10.1186/s12885-019-6276-y contributor: fullname: Cao – volume: 17 year: 2021 ident: B13 article-title: Expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer publication-title: Future Oncol doi: 10.2217/fon-2020-0683 contributor: fullname: Wang – volume: 10 year: 2021 ident: B20 article-title: Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma publication-title: Oncoimmunology doi: 10.1080/2162402X.2021.1933332 contributor: fullname: Yin – volume: 450 year: 2019 ident: B7 article-title: PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways publication-title: Cancer Lett doi: 10.1016/j.canlet.2019.02.022 contributor: fullname: Wei – volume: 20 start-page: 140 year: 2022 ident: B36 article-title: SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma publication-title: J Trans Med doi: 10.1186/s12967-022-03342-6 contributor: fullname: Yang – volume: 99 year: 2021 ident: B39 article-title: Programmed death ligand 1 expression as a prognostic marker in patients with advanced biliary tract cancer publication-title: Oncology doi: 10.1159/000514404 contributor: fullname: Kim – volume: 20 year: 2019 ident: B41 article-title: A critical insight into the clinical translation of PD-1/PD-L1 blockade therapy in clear cell renal cell carcinoma publication-title: Curr Urol Rep doi: 10.1007/s11934-019-0866-8 contributor: fullname: Nunes-Xavier – volume: 6 year: 2013 ident: B43 article-title: Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma publication-title: Trans Oncol doi: 10.1593/tlo.13256 contributor: fullname: Kang – volume: 7 year: 2020 ident: B46 article-title: Anti-PD-1 immunotherapy and radiotherapy for stage IV intrahepatic cholangiocarcinoma: a case report publication-title: Front In Med doi: 10.3389/fmed.2020.00368 contributor: fullname: Liu – volume: 12 year: 2021 ident: B24 article-title: PD-1 inhibitors plus capecitabine as maintenance therapy for advanced intrahepatic cholangiocarcinoma: a case report and review of literature publication-title: Front In Immunol doi: 10.3389/fimmu.2021.799822 contributor: fullname: Wang – volume: 31 start-page: 291 year: 2020 ident: B49 article-title: Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma publication-title: Endocr Pathol doi: 10.1007/s12022-020-09630-5 contributor: fullname: Girolami – volume: 34 start-page: 798 year: 2021 ident: B37 article-title: Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes publication-title: Modern Pathol doi: 10.1038/s41379-020-00702-9 contributor: fullname: Yugawa – volume: 372 year: 2021 ident: B27 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ doi: 10.1136/bmj.n71 contributor: fullname: Page – volume: 12 year: 2022 ident: B47 article-title: Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems publication-title: J Pers Med doi: 10.3390/jpm12071073 contributor: fullname: Marletta – volume: 52 year: 2019 ident: B8 article-title: PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway publication-title: Cell Prolif doi: 10.1111/cpr.12571 contributor: fullname: Zhao – volume: 249 start-page: 52 year: 2019 ident: B9 article-title: Terwisscha van scheltinga AG, et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells publication-title: J Pathol doi: 10.1002/path.5280 contributor: fullname: Stutvoet – volume: 29 start-page: 44 year: 2019 ident: B10 article-title: WNT signaling in cancer immunosurveillance publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2018.08.005 contributor: fullname: Galluzzi – volume: 12 year: 2017 ident: B18 article-title: PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis publication-title: PloS One doi: 10.1371/journal.pone.0182692 contributor: fullname: Gu – volume: 112 year: 2015 ident: B40 article-title: IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer publication-title: Br J Cancer doi: 10.1038/bjc.2015.101 contributor: fullname: Abiko – volume: 11 year: 2016 ident: B12 article-title: PD-L1 expression in lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.04.014 contributor: fullname: Yu – volume: 327 year: 2003 ident: B30 article-title: Measuring inconsistency in meta-analyses publication-title: BMJ doi: 10.1136/bmj.327.7414.557 contributor: fullname: Higgins – volume: 10 year: 2022 ident: B44 article-title: Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: a case report publication-title: World J Clin cases doi: 10.12998/wjcc.v10.i27.9743 contributor: fullname: Zhu – volume: 13 year: 2020 ident: B25 article-title: Olaparib and pembrolizumab treatment for -mutated and PD-L1-Positive intrahepatic cholangiocarcinoma recurrence and metastasis: a case report publication-title: OncoTargets Ther doi: 10.2147/OTT.S250454 contributor: fullname: Xiong – volume: 8 start-page: 16 year: 2007 ident: B28 article-title: Practical methods for incorporating summary time-to-event data into meta-analysis publication-title: Trials doi: 10.1186/1745-6215-8-16 contributor: fullname: Tierney – volume: 40 year: 2017 ident: B14 article-title: Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma publication-title: J Immunother doi: 10.1097/CJI.0000000000000187 contributor: fullname: Huang – volume: 70 start-page: 73 year: 2018 ident: B42 article-title: PD-1 and cancer: molecular mechanisms and polymorphisms publication-title: Immunogenetics doi: 10.1007/s00251-017-1015-5 contributor: fullname: Salmaninejad – volume: 9 year: 2020 ident: B34 article-title: Clinicopathological and prognostic implications of vessels encapsulate tumor clusters with PD-L1 in intrahepatic cholangiocarcinoma patients publication-title: Trans Cancer Res doi: 10.21037/tcr.2020.04.11 contributor: fullname: Tao – volume: 8 year: 2017 ident: B21 article-title: Expression of PD-L1 and prognosis in breast cancer: a meta-analysis publication-title: Oncotarget doi: 10.18632/oncotarget.15532 contributor: fullname: Zhang – volume: 18 start-page: 303 year: 2020 ident: B35 article-title: PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome publication-title: World J Surg Oncol doi: 10.1186/s12957-020-02082-5 contributor: fullname: Tian – volume: 14 start-page: 39 year: 2021 ident: B23 article-title: Clinicopathological and prognostic significance of immunoscore and PD-L1 in intrahepatic cholangiocarcinoma publication-title: OncoTargets Ther doi: 10.2147/OTT.S288982 contributor: fullname: Wu – volume: 126 year: 2022 ident: B32 article-title: Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma publication-title: Br J Cancer doi: 10.1038/s41416-021-01569-6 contributor: fullname: Lan – volume: 11 year: 2020 ident: B17 article-title: Correlation of PD-L1 and SOCS3 Co-expression with the prognosis of hepatocellular carcinoma patients publication-title: J Cancer doi: 10.7150/jca.46158 contributor: fullname: Chen – volume: 48 year: 2018 ident: B3 article-title: Regulation and function of the PD-L1 checkpoint publication-title: Immunity doi: 10.1016/j.immuni.2018.03.014 contributor: fullname: Sun – volume: 8 year: 2018 ident: B5 article-title: Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion publication-title: Front In Oncol doi: 10.3389/fonc.2018.00386 contributor: fullname: Dong |
SSID | ssj0000493335 |
Score | 2.4043643 |
SecondaryResourceType | review_article |
Snippet | Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic... Background Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the... BackgroundProgrammed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 1119168 |
SubjectTerms | B7-H1 Antigen - metabolism Bile Duct Neoplasms Bile Ducts, Intrahepatic - metabolism Cholangiocarcinoma Humans Immunology intrahepatic carcinoma Ligands meta-analysis Neoplasm Recurrence, Local Prognosis prognostic value programmed cell death 1 (PD-1) programmed cell death ligand 1 (PDL1) |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhEMiltE0f2xcq9FbcWJatR25JaAiFlhwSyE2MbU3i0pXLZhfaU_56Z2wn7JZCL7nKxh7PN9J8I49mhPiQRx1zRE7F8S4rq7rNaq901pSQg7FYueGg8Ndv5vSi_HJZXa61-uKcsLE88Ki4fRvRgKJZwD28FShnwStw2hU1xrxth9U392vB1PeR92qtq_GUDEVhfh-7-Xz1iZuF8ypBpMhteKKhYP-_WObfyZJr3ufksXg00UZ5OIr7RGzF9FTsjI0kf--J27NFzxlzdFVy-e4oe5RT6hU9VPL2vGyZ7ckf3RWkVioZf005sEl2SU71VW8kb8zSAAlxHXmwkUP4m6468nqLpkv9HA4kyHlcQgZTSZNn4uLk8_nxaTa1ViAQjF9m6FXbWKuURSIkWFsoGueMcxXEkhhgAXntbNQlQoFtZWnWOtRVS-6OArim0s_FdupTfCkk74PohiApbF0adKDRGIAGsabv8nomPt6pOfwcK2gEijwYlDCAEhiUMIEyE0eMxP2dXP16GCCbCJNNhP_ZxEy8v8Mx0GxhHUOK_eomFI4oZamdJbFejLjev0pTvE5LrpkJt4H4hiybV1J3PVTk5obH3uXm1UNI_1rsskb4l5Wyb8T2crGKb4n5LOt3g5H_AYGdBCo priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3daxQxEA-1Ivgiav04rSVC32TrZrObZAUptliKoPjgQd_C7G5y3dLL6t4dtE_-687s5oonLfia7Ecyv53Mb7KTGcb2Uydd6j2F4pQmyYuqSapSyKTOIQWlfWGGg8Jfv6nTaf7lrDjbYutyR1GAi1tdO6onNe0vD65-XR-iwn8kjxPt7XvfzuerA6oDTgsA8h1zj93PcvTUKZQv0v2LkQ1LKYvx7Mwdt27YpyGN_23c898Qyr9s0slj9iiSSf5pRP8J23LhKXswlpe83mG_v_cdxdFhL6ek3o53nseALHwop0173hAH5JftDELDBXdXMTI28DbwmHV1wWm7FhtwEOeOGms-SC7MWrSFfd2Gbg4fOPC5W0ICMdHJMzY9-fzj-DSJBRcQGlUuE1-KptZaCO2RpvhKQ1Ybo4wpwOXICzNIK6OdzD1kvik06rLxsmjQCKJbVxfyOdsOXXAvGafdEVkLMJmucuUNSK8UQO19hfMq5YS9W4vZ_hzzalj0RwgUO4BiCRQbQZmwI0Li5krKiT00dP3MRhWz2nkFAtdLqvYuQBgNJQ5AmqzyLm2aCXu7xtGiDpGMIbhutbCZQaKZS6NxWC9GXG9eJdGLx4VYTZjZQHxjLJs9oT0f8nRTGeTSpOrVf7z4NXtIE6b_VELvsu1lv3JvkO4sq73hG_4DYLICEw priority: 102 providerName: Scholars Portal |
Title | Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37138876 https://search.proquest.com/docview/2809543873 https://pubmed.ncbi.nlm.nih.gov/PMC10149806 https://doaj.org/article/7ef6a176323941a187a91a8382bfe0dd |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaSkhcEG-WR2Ukbii7cZzYDjeoKBXSoh6otLdo4tjboMaptrsSnPjrzDhJ1UWcuPhg5zHx58c3k_EMY-9SJ13qPbnilCbJi7pJ6lLIxOaQgtK-MPGg8PKbOrvIv66K1QFT01mY6LRv63Yerrp5aC-jb-V1ZxeTn9jifHlC-WVLk6rFITvEEXpHR_8xcF4pZTGckEENrFz4tut2c0oUTisEEiKztwvFYP3_Yph_O0re2XlOH7IHI2XkHwfRHrEDFx6ze0MSyV9P2O_zTU_ectjKKXS3473no9sVPpSTaZ43xPT4VbuG0HDB3c_R_zXwNvAxtuoNJ6MsVqAQl44qLY-qb1i3uONtbBv6Dj5w4J3bQgJjOJOn7OL08_eTs2RMq4AAqHKb-FI0VmshtEcy4msNmTVGGVOAy5H9ZZDWRjuZe8h8U2icscbLosGtDpU3W8hn7Cj0wb1gnGwg0gowma5z5Q1IrxSA9b7G7yrljL2furm6HqJnVKh1EChVBKUiUKoRlBn7REjcXkmRr2NFv1lXI_6Vdl6BwFWRcroLEEZDiQJIk9XepU0zY28nHCucKdTHEFy_u6kyg3Qyl0ajWM8HXG9fJVFXx-VWzZjZQ3xPlv0WHJwxGvc0GF_-_62v2H3qB_pJJfRrdrTd7Nwb5Drb-jjaCLD8shJYLnNzHAf7H6b5Bkk |
link.rule.ids | 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEYIL78fyNBI3lGwcJ7bTW1tRLdCtemhFb5bt2NtA41TbrARc-Osd51F1Ky5wtRNl7BmPv3E-zyD0IbHUJs4FKk4hoizXZaQLQiOTqUQx7nLRXRSeH7DZcfblJD_ZQGy8C9OR9o2uYn9Wx7467biV57WZjjyx6eF8N9SXLUTCprfQbViwSXYtSv_eo15Kad7fkYEYrJi6qq5XcSgVHnwEQCKxtg916fr_hjFvUiWv7T17D9C3UeqecvIjXrU6Nr9vJHT892E9RPcHOIq3-_5HaMP6x-hOX6Dy1xP053DZBCYe9OKQFtzixuGB0gXi4nDsj8uAIvFZtVC-xATbnwO31uPK4yFv6wUOB77QAMM7taHR4C6s9osKdtOlqXxTqy2scG1bFakhVcpTdLz36Wh3Fg0lG0C5rGgjV5DScE4IdwB0nOYqNUIwIXJlM0CWqUq04JZmTqWuzDl4A-FoXsI2CoGhyekztOkbb18gHM5XqCFKpFxnzAlFHWNKGec0jKugE_RxVKA87zNzSIhogrplp24Z1C0HdU_QTtDx1ZMhq3bX0CwXclCC5NYxRcDjhnrxRBHBVQECUJFqZ5OynKD3o4VIWIVhjpW3zepCpgKgakYFB7Ge9xZz9SnKCQVXziZIrNnSmizrPWAhXabv0SJe_v-r79Dd2dF8X-5_Pvj6Ct0LcxJ-hhH-Gm22y5V9A5iq1W-7BXQJ-oElrQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagCMSFN3R5GokbyiaOE9vhBoVVebTaA5UqcYhsx96GNs5qNysBF_4648SpuhWnXu1EGXvG42-czzMIvUkMNYm1nopTiCjLVRWpgtBIZzKRjNtc9BeFDw7Z_lH25Tg_DqzKdaBVOq3qqTtrpq4-6bmVy0bHI08snh_s-fqyhUhYvKxsfB3dgEWbsAuR-s8B-VJK8-GeDMRhRWzrptlMfblw7ycAFomtvahP2f8_nHmZLnlh_5ndRT9GyQfayel006mp_nMpqePVhnYP3QmwFL8fnrmPrhn3AN0cClX-foj-zletZ-RBL_bpwQ1uLQ7ULhAZ--N_XHk0ic_qhXQVJtj8Chxbh2uHQ_7WNfYHv9AAQzwxvlHjPrx2ixp21ZWuXdvId1jixnQykiFlyiN0NPv0fW8_CqUbQMms6CJbkEpzTgi3AHis4jLVQjAhcmkyQJipTJTghmZWprbKOXgFYWlewXYKAaLO6WO041pndhH25yxUEylSrjJmhaSWMSm1tQrGVdAJejsqsVwOGTpKiGy8yste5aVXeRlUPkEfvJ7Pn_TZtfuGdrUogyJKbiyTBDyvrxtPJBFcFiAAFamyJqmqCXo9WkkJq9HPsXSm3azLVABkzajgINaTwWrOP0U5oeDS2QSJLXvakmW7B6ykz_g9WsXTq7_6Ct2af5yV3z4ffn2Gbvsp8f_ECH-OdrrVxrwAaNWpl_0a-gcIASgt |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+programmed+cell+death+ligand+1+expression+in+patients+with+intrahepatic+cholangiocarcinoma%3A+a+meta-analysis&rft.jtitle=Frontiers+in+immunology&rft.au=Xian%2C+Feng&rft.au=Ren%2C+Dacheng&rft.au=Bie%2C+Jun&rft.au=Xu%2C+Guohui&rft.date=2023-04-17&rft.eissn=1664-3224&rft.volume=14&rft.spage=1119168&rft.epage=1119168&rft_id=info:doi/10.3389%2Ffimmu.2023.1119168&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |